Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the PfCRT SVMNT type by Sa, Juliana M & Twu, Olivia
COMMENTARY Open Access
Protecting the malaria drug arsenal: halting
the rise and spread of amodiaquine resistance
by monitoring the PfCRT SVMNT type
Juliana M Sa
1*, Olivia Twu
2
Abstract
The loss of chloroquine due to selection and spread of drug resistant Plasmodium falciparum parasites has greatly
impacted malaria control, especially in highly endemic areas of Africa. Since chloroquine removal a decade ago,
the guidelines to treat falciparum malaria suggest combination therapies, preferentially with an artemisinin deriva-
tive. One of the recommended partner drugs is amodiaquine, a pro-drug that relies on its active metabolite mono-
desethylamodiaquine, and is still effective in areas of Africa, but not in regions of South America. Genetic studies
on P. falciparum parasites have shown that different pfcrt mutant haplotypes are linked to distinct levels of chloro-
quine and amodiaquine responses. The pfcrt haplotype SVMNT (termed after the amino acids from codon positions
72-76) is stably present in several areas where amodiaquine was introduced and widely used. Parasites with this
haplotype are highly resistant to monodesethylamodiaquine and also resistant to chloroquine. The presence of this
haplotype in Africa was found for the first time in 2004 in Tanzania and a role for amodiaquine in the selection of
this haplotype was suggested. This commentary discusses the finding of a second site in Africa with high inci-
dence of this haplotype. The >50% SVMNT haplotype prevalence in Angola represents a threat to the rise and
spread of amodiaquine resistance. It is paramount to monitor pfcrt haplotypes in every country currently using
amodiaquine and to re-evaluate current combination therapies in areas where SVMNT type parasites are prevalent.
Background
The article “Plasmodium falciparum isolates from
Angola show the StctVMNT haplotype in the pfcrt
gene” by Gama BE et al [1] provides results that are
more worrisome than surprising. This paper, along with
a report from Tanzania [2] and a genetic study between
two parasites from Africa and South America [3], high-
lights an urgent need to examine and update treatment
guidelines that use combination therapies with
4-aminoquinolines.
Gama et al examined the prevalence of different hap-
lotypes of the Plasmodium falciparum chloroquine (CQ)
resistance transporter gene pfcrt, and the multiple drug
resistance transporter pfmdr1, from patients in Angola
with uncomplicated malaria in 2007. At that time the
patients were treated with one of the two artemisinin
combination therapies, artemether + lumefantrine or
artesunate + amodiaquine (AQ), in accordance with the
country’s anti-malarial guidelines.
The article reports on the “unexpected” prevalence
(> 50%) of a CQ-resistant pfcrt haplotype often found in
other countries including Brazil, India, Papua New Gui-
nea, and the Philippines (termed SVMNT, based on
codon positions 72-76, Figure 1). Since the characteriza-
tion of pfcrt as the main genetic determinant of CQ
resistance [4] and the removal of CQ from WHO anti-
malarial guidelines in 2000, this is the second report of
this haplotype in Africa. While Gama et al propose that
the commercial relationship between Brazil and Angola
allows for the import of the SVMNT haplotype through
travellers, the report in 2006 by Alifrangis et al sug-
gested a role of AQ in the selection of the SVMNT hap-
lotype in Tanzania [2]. Interestingly, two other reports
from the same countries show contrasting results
regarding the pfcrt haplotype on those areas. The first,
in Uige, Angola, shows that in 2004 no SVMNT type
parasites were detected [5]. The second is a five-year
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type was found in 2006 and 2007 after removal of AQ
[6]. It is not clear whether differential patterns of para-
site transmission levels in distinct geographic locations
or drug policy changes may account for this “patchy”
distribution of SVMNT type parasites. It is also impor-
tant to note that after the spread of CQ resistance in
Brazil and attempts to re-introduce AQ in the late 1980 s
that country showed the highest level of AQ resistance
reported at the time [7]. The appearance and spread of
the SVMNT haplotype in Africa, where AQ has been
widely used in the past decade in combination therapies
should be more expected than surprising.
Discussion
The analysis of the in vitro responses to CQ, AQ, and
its active metabolite monodesethylamodiaquine
(MDAQ) from the P. falciparum genetic cross
7G8xGB4, between a CQ-resistant clone from South
America carrying the SVMNT pfcrt haplotype and an
African clone carrying the CVIET haplotype, showed
that these haplotypes are linked to distinct AQ/MDAQ
and CQ responses [3]. Parasites with the SVMNT
haplotype are highly resistant to MDAQ, but only mod-
erately resistant to CQ, whereas clones with the CVIET
haplotype are moderately resistant to MDAQ and
highly resistant to CQ. These data, coupled with obser-
vations on the historical use of AQ with early trials in
India, Brazil, the Philippines, Laos, Ecuador, Bolivia,
Honduras, and areas of South Pacific (mostly matching
the geographic distribution of the SVMNT haplotype,
Figure 1), suggest that AQ had an early and prominent
role in the selection of drug resistant SVMNT type
parasites. Furthermore, data on the Tanzania genotypes
of P. falciparum infected samples collected in 2003 and
2004, revealed SVMNT haplotype prevalence of 0% and
19%, after the increased use of AQ indicating a strong
and quick evolutionary force. This idea is also sup-
ported by another recent report from Afghanistan,
where the prevalence of P. falciparum SVMNT type has
been associated with AQ resistance [8]. The mechanism
by which different pfcrt haplotypes interact with AQ,
MDAQ, and CQ is yet to be determined, but it may
rely on their specific physicochemical characteristics
such as amino acid side-chain volume, charge, and
hydrophobicity [9].
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Figure 1 Current worldwide distribution of PfCRT types (codons 72-76, based on the report of more than a single parasite isolate).
Regions with previous history of AQ use coincide with areas where the SVMNT haplotype is prevalent. Figure adapted and updated from Sa et al [3].
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carrying the CVIET rather than the SVMNT pfcrt hap-
lotype. While regions in Africa and China where CVIET
was the prevalent, if not exclusive haplotype, have been
repopulated by CQ-sensitive parasites with the CVMNK
haplotype after CQ removal [10-13] regions of South
America have remained saturated by the SVMNT haplo-
type decades after CQ and AQ removal. A reduced fit-
ness cost of the SVMNT haplotype suggests that once
this haplotype is present, and CQ and AQ are removed,
r e p o p u l a t i o no fs e n s i t i v es t r a i n sm a yb ev e r ys l o wt o
occur.
It is essential to reiterate to the scientific community
and government agencies the possibility of this hypoth-
esis: AQ use results in the rapid evolution of 4-amino-
quinoline resistant P. falciparum parasites of the pfcrt
haplotype SVMNT, which easily adapt with relatively lit-
tle fitness cost. The monitoring of pfcrt codon positions
72-76 from P. falciparum infected patients in all coun-
tries using AQ in their treatment guidelines, regardless
of the combination drug is crucial. An estimation of the
current distribution of parasites with this haplotype and
the consideration of complete removal of AQ from
areas of SVMNT prevalence is important because of the
resistance levels of SVMNT parasites and the likelihood
that they will be as fit as the drug-resistant parasites
from South America, where the treatment options of
AQ as well as CQ have long been lost.
Conclusions
T h ec o n t i n u e du s eo fA Qi nc ombination therapies is
dangerous in regions where resistant SVMNT parasites
occur and threatens the selection of parasites resistant
to the partner drug. All efforts should be made to moni-
tor and to halt the selection of SVMNT parasites in
Africa and develop new partners in effective combina-
tion therapies that will protect the anti-malarial arsenal.
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